摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

恩格列酮 | 109229-58-5

中文名称
恩格列酮
中文别名
——
英文名称
englitazone
英文别名
5-[[3,4-dihydro-2-(phenylmethyl)-2H-1-benzopyran-6-yl]methyl]-2,4-thiazolidinedione;5-<(2-benzyl-3,4-dihydro-2H-1-benzopyran-6-yl)methyl>thiazolidine-2,4-dione;5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl] thiazolidine-2,4-dione;5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione;5-(2-benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl)-thiazolidine-2,4-dione;5-[(2-benzyl-3,4-dihydro-2H-chromen-6-yl)methyl]-1,3-thiazolidine-2,4-dione
恩格列酮化学式
CAS
109229-58-5
化学式
C20H19NO3S
mdl
——
分子量
353.442
InChiKey
MVDXXGIBARMXSA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    562.7±19.0 °C(Predicted)
  • 密度:
    1.300±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    80.7
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090

SDS

SDS:8741781345f9b8f639d0f1e07dc7fb04
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    5-<(2-benzyl-3,4-dihydro-2H-1-benzopyran-6-yl)methylene>thiazolidine-2,4-dione 在 palladium on activated charcoal 氢气溶剂黄146 作用下, 以57%的产率得到恩格列酮
    参考文献:
    名称:
    Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents
    摘要:
    A series of dihydrobenzofuran and dihydrobenzopyran thiazolidine-2,4-diones (compounds 3-26) was synthesized from the corresponding aryl aldehydes 1 in two steps. These compounds represent conformationally restricted analogues of the novel hypoglycemic ciglitazone. The series was evaluated by hypoglycemic effects in vitro by measuring stimulation of 2-deoxyglucose uptake in L6 myocytes and stimulation of expression of the glucose transporter protein in 3T3-L1 adipocytes. In vivo hypoglycemic effects were evaluated in the genetically obese ob/ob mouse, and structure-activity relationships are discussed. On the basis of this in vivo potency, we have selected the 2(R)-benzylbenzopyran derivative to be further studied in a clinical setting.
    DOI:
    10.1021/jm00105a050
点击查看最新优质反应信息

文献信息

  • [EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
    申请人:GILEAD APOLLO LLC
    公开号:WO2017075056A1
    公开(公告)日:2017-05-04
    The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
    本发明提供了化合物I和II,这些化合物可用作乙酰辅酶A羧化酶(ACC)的抑制剂,以及它们的组合物和使用方法。
  • NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
    申请人:Ryono Denis E.
    公开号:US20080009465A1
    公开(公告)日:2008-01-10
    Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
    提供了磷酸酯和磷酸酯激活剂,因此在治疗糖尿病和相关疾病方面非常有用,并具有以下结构: 其中 是杂环芳基环; R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ; R 5 和R 6 分别选择自H、烷基和卤素; Y为R 7 (CH 2 ) s 或不存在;以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义;或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
  • [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2016089721A1
    公开(公告)日:2016-06-09
    The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及甲基噁唑化合物,其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
  • New pyrrolidine derivatives, pharmaceutical compositions and uses thereof
    申请人:FLECK Martin
    公开号:US20140100211A1
    公开(公告)日:2014-04-10
    Pyrrolidine derivatives of the formula and their use as medicaments for the treatment of obesity and type 2 diabetes.
    吡咯烷衍生物的化学式及其作为治疗肥胖和2型糖尿病药物的用途。
  • TRIAZOLE ACC INHIBITORS AND USES THEREOF
    申请人:Gilead Apollo, LLC
    公开号:US20170166584A1
    公开(公告)日:2017-06-15
    The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
    本发明提供了三唑化合物,可用作乙酰辅酶A羧化酶(ACC)的抑制剂,以及其组合物和使用方法。
查看更多